Last reviewed · How we verify
NCT04336215
Rutgers COVID-19 Cohort Study
trial testing Non-Interventional in Coronavirus in 829 participants. Status unknown.
31 August 2024
Quick facts
| Lead sponsor | Rutgers, The State University of New Jersey |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 829 |
| Start date | 7 April 2020 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 August 2024 |
| Sites | 7 locations across United States |
Drugs / interventions tested
- Non-Interventional
Conditions studied
- Coronavirus — all drugs for Coronavirus →
- SARS-CoV-2 — all drugs for SARS-CoV-2 →
Sponsor
Rutgers, The State University of New Jersey
Who can join
20 and older, any sex, with Coronavirus or SARS-CoV-2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Our long-term goal is to protect the health care workforce (HCW) caring for SARS-CoV-2-infected patients, their families, communities, and the general population. Our specific objective is to rapidly establish a prospective cohort to characterize the factors related to viral transmission and disease severity in a large healthcare system. We addressed this hypothesis by recruiting and longitudinally following 546 HCW and a comparison group of 283 non-HCW within a large academic health system, Rutgers Biomedical and Health Sciences (RBHS). By intensively following participants over a several year period (2020-2024) and collecting serial biospecimens (nasopharyngeal/throat swabs, blood, and saliva) and questionnaire data at multiple time points, we will uniquely characterize SARS-CoV-2 transmission and risk factors for COVID-19 among HCW and our larger academic community.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study.
Horton DB, Barrett ES, Roy J, Gennaro ML, et al · · 2021 · cited 24× · PMID 34387310 · DOI 10.1093/infdis/jiab411 -
Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection and vaccination.
Datta P, Ukey R, Bruiners N, Honnen W, et al · · 2021 · cited 11× · PMID 34634317 · DOI 10.1016/j.jim.2021.113165 -
Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection
Datta P, Ukey R, Bruiners N, Honnen W, et al · · 2021 · DOI 10.1101/2021.07.09.21260266 -
Vaccination boosts protective responses and counters SARS-CoV-2-induced pathogenic memory B cells
Mishra PK, Bruiners N, Ukey R, Datta P, et al · · 2021 · DOI 10.1101/2021.04.11.21255153 -
Prevalence of SARS-CoV-2 infection in previously undiagnosed health care workers at the onset of the U.S. COVID-19 epidemic
Barrett ES, Horton DB, Roy J, Gennaro ML, et al · · 2020 · DOI 10.1101/2020.04.20.20072470
Verify or expand the search:
- PubMed search for NCT04336215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-Interventional
Trials testing the same drug.
- NCT06412029 — Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practices · enrolling by invitation
- NCT05568459 — A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standa · active not recruiting
- NCT06527508 — Construct Validity and Intra-Observer Reliability of the SDQ · completed
- NCT05919511 — Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease · recruiting
- NCT05510908 — Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC · completed
Other recruiting trials for Coronavirus
Currently open trials in the same condition.
- NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
- NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
- NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
- NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
- NCT04568148 — COVID-19 Biorepository · active not recruiting
Other Rutgers, The State University of New Jersey trials
Trials by the same sponsor.
- NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
- NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
- NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
- NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
- NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04336215 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04336215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing